• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: docosahexanoic acid-paclitaxel
Date Designated: 03/05/2001
Orphan Designation: Treatment of hormone-refractory prostate cancer.
Orphan Designation Status: Designated/Withdrawn
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Luitpold Pharmaceuticals, Inc.
One Luitpold Drive
Shirley, New York 11976
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.